Update on treatment aspects of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

IVAN HOFFMANN1, ADRIAN PILATZ1, GIANPAOLO PERLETTI2,3, VITTORIO MAGRÌ4, FLORIAN M.E. WAGENLEHNER1

1 Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Germany
2 Department of Theoretical and Applied Sciences, Biomedical Research Division, Università degli Studi dell’Insubria, Busto Arsizio/Varese, Italy
3 Department of Basic Medical Sciences, Facoltà di Medicine and Health Sciences, Ghent University, Ghent, Belgium
4 Urology Secondary Care Clinic, Azienda Ospedaliero Istituti Clinici di Perfezionamento, Milan, Italy

Abstract: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a frequent disease affecting men of all ages. Chronic prostatitis can significantly impair quality of life. Symptoms attributed to CP/CPPS are heterogeneous with a broad range of signs and symptoms. A clinical phenotyping system has been suggested to classify patients with CP/CPPS clinically and symptomatically resulting in a unique clinical phenotype. Research efforts were made to define multimodal therapeutic strategies addressing the wide array of signs and symptoms. The upregulation of the corticotropin-releasing hormone has been suggested as a hormonal risk factor. Chlamydia trachomatis11, Ureaplasma urealyticum12, Mycoplasma hominis13, Trichomonas vaginalis14, Viruses15, Candida16 and parasites have been described to be associated with the infectious forms of CP/CPPS. Monotherapy strategies for CP/CPPS have been shown to be ineffective17. These discouraging results show that the complex symptom array of CP/CPPS patients cannot be targeted by a single therapeutic agent. The UPOINT/UPOINTS system has been proposed in order to classify patients with CP/CPPS clinically and to offer patients a symptom related therapy.

INTRODUCTION

According to the National Institutes of Health (NIH) 1995 classification Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) represents category III of prostatitis with no bacteria detectable in urine or expressed prostatic secretion. CP/CPPS can be inflammatory with an elevated white cell count in prostatic secretion (NIH IIIa) or non-inflammatory with no white cells in the prostatic secretion (NIH IIIb). The leucocyte count does not correlate with the severity of symptoms2. The worldwide prevalence of CP/CPPS is between 2.7 and up to 16%3,4. CP/CPPS has a significant negative impact on quality of life6. In a large European study 21% of patients with chronic pain syndrome had a depressive state18,19. Patients with CP/CPPS are heterogeneous and symptomatology profile resulting in an unique clinical phenotype. Research efforts were made to define multimodal therapeutic strategies addressing the wide array of signs and symptoms. A clinical phenotyping system has been suggested clinically directive to focus on the symptoms of the patients. This system contains six major complaint domains of CP/CPPS patients: urinary, psychosocial, organ specific, infection, neurologic and tenderness of skeletal muscles (UPOINT). Recently, the system was modified by adding the sexual dysfunction as a domain to create UPOINTS. Promising results have currently been reported from multimodal approaches of CP/CPPS therapy as it aims to offer a personalized combination therapy.

Key words: Prostatitis; Chronic pelvic pain syndrome; UPOINTS; Phenotype; Treatment.

METHODS

We performed a selective literature search for chronic prostatitis/chronic pelvic pain syndrome.

RESULTS

As there are no biomarkers of CP/CPPS to guide therapy the validated outcome index is the National Institute of Health Chronic Prostatitis Index (NIH-CPSI)20. A clinical phenotyping was proposed to classify patients with CP/CPPS to offer therapy according to the individual complaints. The UPOINT system was validated in several clinical trials21,22. A strong correlation between the number of positive UPOINT domains and the total score of the NIH-Chronic Prostatitis Symptom Index (CPSI) measured in patients was shown. Shokes et al.21 first demonstrated that a majority (84%) of patients treated based on the UPOINT phenotype had a clinical improvement of CP/CPPS symptoms measured by an at least 6-point improvement in the total score of the NIH-CPSI symptom questionnaire. This strategy was followed in other studies22.

In a large German-Italian study, a total of 1,227 patients with CP/CPPS were evaluated. The correlation between the UPOINT and CP/CPPS was confirmed for the total and for the Italian subgroup whereas, in the German subgroup the correlation was achieved only after sexual dysfunction (ED) was added as a domain to create UPOINTS22. The authors suggested that adding sexual dysfunction to the domain system may be helpful, as sexual dysfunction is a frequent complaint of patients suffering from CP/CPPS. Two additional studies from China and Canada supported this observation23,24. The prevalence of sexual dysfunction is 65%25. CP/CPPS has been clearly shown as a risk factor of ED22.

Several therapy options are available for each UPOINT domain. In a prospective randomised placebo-controlled study Pollen extract (Cermilton) was shown to significantly improve the total score of the NIH-CPSI as well as the pain and the quality of life domains in patients with inflammatory CP/CPPS (NIH IIIa)26. The treatment with Pollen extracts can be more helpful when supplements are added27. Alpha-receptor blockers alone and with Pollen extract improve urinary flow parameters in patients with prostatitis28,29. The probability of the beneficial effects of alpha-receptor blockers is higher in the presence of storage and voiding symptoms in CP/CPPS patients (U in UPOINT)30. Even though 5-alpha-reductase

http://www.pelviperineology.org
inhibitors are not recommended in general (EAU Guidelines 2017)

some studies showed a tendency to improve symptoms. Phosphodiesterase-5 inhibitors may help to improve sexual func-
tion. Antidepressants may be effective to treat the neurological do-
main of the UPOINT system. Xia et al. reported that an antidepres-
sive therapy with Fluoxetin not only had a positive effect on the de-
pression score but also significantly improved the quality of life and
urinary domains of CPSI. Special phytotherapy treatment options
such as myofascial physical therapy may be helpful as it releases
tightness of soft tissue and helps to release pain. Acupuncture
has been shown to be an effective therapy especially in decreasing
pain. According to the EAU guidelines NSAIDs have a moderate
treatment effect. Celecoxib was shown to be significantly beneficial
such as myofascial physical therapy may be helpful as it releases

In placebo-controlled studies antibiotics were proven not to sig-
ificantly improve the symptoms of CP/CPPS if no infection in pro-
state is present. In contrast to these findings a network meta-

analysis showed a significant benefit of antibiotic treatment in total
symptom, pain, and QoL scores in CP/CPPS patients. In the EAU
guidelines the use of quinolones or tetracyclin for a treat-
ment period of at least six weeks is recommended if an antibiotic
treatment is applied (EAU Guidelines 2017). It has been assumed
that an antibiotic treatment helps in cases of an infectious cause of
CP/CPPS when microbiological cultures failed to detect
uro pathogens that are present in the prostatic fluid. In 8% of patients
with suggested CP/CPPS positive prostatitis cultures can be found.

Investigations show that treatment of some UPOINT(S) domains
may be beneficial for other domains. In a large Italian study patients
with CP/CPPS NIH-III were treated with alpha-receptor blocker al-
fuzosin and S repens extract alone or in combination with supple-
ments lycopene and selenium. Only a positive microbiologi-
culate of prostate-specific specimen an antibiotic ciprofloxacin
or azithromycin was added to the therapy. Although no therapy for
the erectile dysfunction was given 54% of patients had an improve-
ment of sexual function. The authors suggested a two-step algo-
rythm for CP/CPPS patients. As a first treatment option a combina-

tion of an alfa-blocker, phytotherapy (pollen extract) optional with
supplements lycopene and selenium and in the case of proven or
highly suspected infection an antibiotic agent. In case of persist-
ent complains antidepressant, anxiolytics, myorelaxants and other
agents can be added as a second step to the treatment.

CONCLUSION

The recent treatment strategies of CP/CPPS take into account the
multimodal origin of this disease as well as its heterogenous pheno-
type. There are diverse options available for patients and treating
tdoctors to achieve significant symptom relief. Clinical results are
promising so far. Based on the modern understanding of the etio-

logy, future investigations may provide further therapeutic options in
a multimodal setting. However, treatment of CP/CPPS remains
challenging and requires from the treating doctor fundamental
knowledge in different fields of modern medicine.

REFERENCES

1. Nickel JC, Alexander RB, Anderson R, Berger R, Comiter CV, Datta NS,
Fowler JE, Krieger JN, Landis JR, Litwin MS, McNaughton-Collins M,
O’Leary MP, Pontari MA, Schaeffer AJ, Shokes DA, White P, Kusk J,
Nyberg L. Chronic Prostatitis Collaborative Research Network Study
Groups. Category III chronic prostatitis/chronic pelvic pain syndrome:
insights from the National Institutes of Health Chronic Prostatitis
320-7.

2. Schaeffer AJ. Epidemiology and demographics of prostatitis. Androl-

3. Krieger JN, Ross SO, Riley DE. Chronic prostatitis: epidemiology and

Symptoms suggestive of chronic pelvic pain syndrome in an urban pop-
ulation: prevalence and associations with lower urinary tract symptoms

2009, 23 (4), 593-610.

chronic pain in Europe: prevalence, impact on daily life, and treatment.

7. Nickel JC, Shokes DA. Phenotypic approach to the management of the
chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2010 Nov;
106 (9), 1252-63.

8. Chuang YC, Weng SF, Hsu YW, Huang CL, Wu MP. Increased risks of
healthcare-seeking behaviors of anxiety, depression and insomnia among
patients with bladder pain syndrome/interstitial cystitis: a nationwide


genesic factors underlie chronic pain syndromes. Pain. 2014 Aug, 155
(8), 1562-8.

10. Tunitsky E, Barber MD, Jeppson PC, Natter B, Jelovsek JE, Ridgeway
Jan; 187 (1), 148-52.

Toni M, Benedoli D. Isolation of Chlamydia trachomatis from the prosta-

12. Weidner W, Brunner H, Krause W. Quantitative culture of ureaplasma
urealyticum in patients with chronic prostatitis or prostatosis. J Urol.
1980 Nov; 134 (5), 622-5.

urealyticum and Mycoplasma hominis in prostatitis. J Infect Dis. 1983
May; 147 (5), 807-13.

S, Desnica B, Zeljko J. Chronic prostatitis caused by Trichomonas vagi-

40 (2), 165-7.

16. Goltz R, Mendling W. Candidiasis of the prostate: a rare form of endomy-

monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain

of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome
who have failed traditional management. Rev Urol. 2007 Spring; 9 (2),
63-72.

19. Stones RW, Selfe SA, Fransman S, Horn SA. Psychosocial and economic

20. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun
EA, Pontari MA, Alexander RB, Farrar JT, O’Leary MP. The National
Institutes of Health chronic prostatitis symptom index: development and
validation of a new outcome measure. Chronic Prostatitis Collaborative

21. Shokes DA, Hakim L, Ghoneim M, Jackson CL. Long-term results of
multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome.

therapy for category III chronic prostatitis/chronic pelvic pain syndrome
in UPOINT’s phenotyped patients. Exp Ther Med. 2015 Mar; 9 (3),
658-666.

23. Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG,
Weidner W. Use of the UPOINT chronic prostatitis/chronic pelvic pain
syndrome classification in European patient cohorts: sexual function do-

24. Davis SN, Binik YM, Ansell R, Carrier S. Is a sexual dysfunction domain
important for quality of life in men with urological chronic pelvic pain

25. Zhao WP, Zhang ZQ, Li XD, Yu D, Rui XF, Li GH, Ding QG. Celecoxib
reduces symptoms in men with difficult chronic pelvic pain syndrome O

26. Li HF, Kang DY. Prevalence of sexual dysfunction in men with chronic
2012 Jun; 34 (7), 1009-17.

10 (10), e0144447.

28. Wagenlehner FM, Schneider H, Ludwig M, Schmitz J, Brähler E,
Weidner W. A pollen extract (Cernilton) in patients with inflammatory

Correspondence to:
Prof. Dr. F.M.E. Wagenlehner
Clinic of Urology, Pediatric Urology and Andrology
Justus-Liebig University Giessen
Rudolf-Buchheim Str. 7
35392 Giessen, Germany
E-mail: florian.wagenlehner@chirurgi.med.uni-giessen.de

Multidisciplinary comment

We have read the review by Hoffmann et al. regarding the treatment of chronic prostatitis/chronic pelvic pain syndrome with interest. According to the National Institute of Health classification for prostatitis, there are 4 different types of prostatitis syndromes1,2. Syndromes I&II have a proven bacterial infection (acute and recurrent respectively), allowing a fairly straightforward approach. Syndrome IV is asymptomatic and so rarely requires treatment. Hoffmann et al. in their review have focused on category III, in which no source of infection is found. These patients may or may not have inflammatory findings in the semen (IIIA and IIIB respectively), in either case they are symptomatic.

Patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) typically present primarily with chronic pain and as such have a strong negative impact on their quality of life. The UPOINT classification system, initially described in 2009, uses a clinical phenotype-based system that helps to profile specific patients and assists in choosing individual treatment targets4. Treatment results are usually assessed using the NIH-CPSI score5.

Without a clear cause, management of CPPS is challenging and frustrating to both the patient and physician, also involving a significant economic burden6. Patients with CPF/CPPS typically have a history of repeated physician visitations, involving multiple doctors. These patients typically undergo multiple diagnostic investigations and treatment trials. Sadly, as described by the authors, although several therapeutic agents exist, they are moderately effective at best, and these patients frequently require multimodality strategies. Considering this, patients suffering from CPF/CPPS can benefit from referral to centers of excellence experienced in treating them. Centers of excellence can reduce unnecessary diagnostic tests, reassure patients regarding their diagnosis and prognosis, and implement an early individualized multimodal therapeutic regimen achieving the best long-term results.

REFERENCES


* Correspondence to:
Uri Netz MD, Dpt Surgery A, Soroka University Medical Center, Beer-Sheva, Israel, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.